Compositions exhibiting inhibition of cyclooxygenase-2

A composition and extract technology, applied in the field of selective inhibition of COX-2-mediated prostaglandin synthesis, can solve the problem of no controlled clinical trials that can ensure safety and efficacy, attacking osteoarthritis, preparations without a history of use, etc. question

Inactive Publication Date: 2009-05-27
METAPROTEOMICS
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] However, existing glucosamine formulations have not been formulated to optimally attack the underlying cause of and alleviate osteoarthritis and rheumatoid arthritis
Also, like many commercially available herbal and dietary supplements, the formulations available have no history of use and no controlled clinical trials to assure their safety and efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions exhibiting inhibition of cyclooxygenase-2
  • Compositions exhibiting inhibition of cyclooxygenase-2
  • Compositions exhibiting inhibition of cyclooxygenase-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] CO of hops 2 Cyclooxygenase-2-mediated selective inhibition of prostaglandin E2 by extracts

[0076] This example exemplifies the CO 2 Excellent COX-2 selectivity of hop extracts. Therefore, it is inferred that the CO of the present invention 2 The potency of the hop extract would be superior to that of the pure compound humulones described in the prior art.

[0077] CO of hops 2 COX-2-mediated PGE 2Produced Inhibition-Equipment-Analytical Balancer, Ohaus Explorer (Ohaus Model #EO1140, Switzerland); Biosafety Cabinet (Forma Model #F1214, Marietta, Ohio); Pipette, 100 to 1000 μL (VWR Cat #4000-208 , Rochester, NY); hand cell counter (VWR catalog #23609-102, Rochester, NY); CO 2 Incubator (Forma Model #F3210, Marietta, Ohio); Hemocytometer (Hausser Model #1492, Horsham, PA); Inversion Microscope (Leica Model #DM IL, Wetzlar, Germany); Multichannel Pipette, 12 Channels ( VWR Cat. No. #53501-662, Rochester, NY); Pipette Aid (Pipet Aid) (VWR Cat. No. #53498-103, Roche...

Embodiment 2

[0112] Synergistic inhibition of prostaglandin E2 production in murine B cells by curcuminoids and hop extract

[0113] This example illustrates the superior COX-2 inhibitory potency and selectivity of curcuminoids of the invention in combination with hop extract compared to curcuminoids alone.

[0114] COX-2-mediated inhibition of PGE2 production in RAW 264.7 cells - Equipment - Analytical Balancer, Ohaus Explorer (Ohaus Model #EO1140, Switzerland); Biosafety Cabinet (Forma Model #F1214, Marietta, Ohio); Pipettes , 100 to 1000 μL (VWR Cat. #4000-208, Rochester, NY); Hand Cell Counter (VWR Cat. #23609-102, Rochester, NY); CO 2 Incubator (Forma Model #F3210, Marietta, Ohio); Hemocytometer (Hausser Model #1492, Horsham, PA); Inversion Microscope (Leica Model #DM IL, Wetzlar, Germany); Multichannel Pipette, 12 Channels ( VWR Cat. #53501-662, Rochester, NY); Pipette Auxiliary (VWR Cat. #53498-103, Rochester, NY); Pipette, 0.5 to 10 μL (VWR Cat. #4000-200, Rochester, NY) ; Pipett...

Embodiment 3

[0154] Normalization of joint function after trauma

[0155] A representative composition of the invention as a dietary supplement will be in the form of an oral formulation, i.e. a tablet, which will provide one of the following combinations: (a) 15 mg curcuminoids / kg / day and 6.0 mg humulone / kg / day day; (b) 15 mg curcuminoids / kg / day and 6.0 mg lupulone / kg / day; (c) 15 mg curcuminoids / kg / day and 6.0 mg dihydroisohumulone / kg / day. Normalization of joint motion following physical trauma due to exercise or repetitive motion stress is expected to occur after 2 to 10 doses. This result was expected in all animals.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method of treating diabetes by administering to an individual having diabetes a composition containing a hops extract. In a particular embodiment, an individual having diabetes can be administered a composition comprising a first component selected from the group consisting of alpha acids and beta acids, essential oils, fats and waxed, with the proviso that the first component and second component are not the same compound. The invention additional provides a method of treating diabetes by administering to an individual having diabetes a composition comprising a first component selected from a curcuminoid and a second component selected from an alpha acid and a beta acid.

Description

[0001] This application is a continuation-in-part of application 09 / 885,721 filed June 20, 2001, which is incorporated herein by reference; and a continuation-in-part of application 10 / 282,236, filed October 25, 2002, which claimed the October 2001 Priority to now-abandoned provisional application 60 / 335,062, filed on the 26th, which is incorporated herein by reference. field of invention [0002] The present invention generally relates to a composition comprising a complex mixture of active ingredients that selectively or synergistically inhibit the expression and / or activity of inducible cyclooxygenase-2 (COX-2), and to A method of selectively inhibiting COX-2-mediated prostaglandin synthesis. More specifically, the composition comprises a mixture of active ingredients isolated from hops (Humulus lupulus) extract, or curcuminoid species as a first component and active ingredients isolated from hops (Hamulus lupulus) extract ingredients as the second component. The composit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): H05B3/68H05B3/02H05B3/10H01L21/00H01L21/02H01L21/205H05B3/12H05B3/14H05B3/74
CPCA61K31/12A61K45/06A61P3/00A61P3/10A61K2300/00A61K36/9066
Inventor J·G·巴比施
Owner METAPROTEOMICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap